Skip to main content

05-08-2022 | JAK inhibitors | Video | Article

Have the ORAL Surveillance results changed rheumatology practice?


Speakers: Richard Conway and Kevin Winthrop

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect (17:12).

00:00 Introduction and overview of the trial results
03:54 Impact on current prescribing decisions
05:51 Considerations with VTE and cancer risk considerations
07:56 Risk:benefit considerations in individual patients
09:21 Do the ORAL Surveillance results represent a class effect?
12:03 First and second line treatment options
14:00 Are there differences between adalimumab and etanercept?
14:56 Lessons learned and future research priorities

About the contributors

Richard Conway

Richard Conway is currently a consultant rheumatologist and physician at St. James’s Hospital and a clinical associate professor at Trinity College Dublin. Disclosures

Full biography

Kevin Winthrop

Kevin Winthrop is Professor of Infectious Diseases and Ophthalmology at the School of Medicine and a Professor of Public Health at the OHSU-PSU School of Public Health at Oregon Health & Science University (OHSU) in Portland, Oregon, USA. Disclosures

Full biography


New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Related content

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy